Drug Type Universal CAR-T |
Synonyms CD19-UCART - EdiGene, ET 02, ET-02 + [3] |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Clinical | China | 20 Jul 2021 | |
B-Cell Malignant Neoplasm | Clinical | China | 20 Jul 2021 | |
Non-Hodgkin Lymphoma | Clinical | China | 20 Jul 2021 |